Disease Extent, Histology, and Long-Term Outcomes in Male Germ Cell Tumors: A Retrospective Cohort Study

Background and Objectives: Germ cell tumors (GCTs) are highly curable, but outcomes vary by stage, prognostic risk, and delivery of treatment. We describe presentation, treatment, and long-term outcomes in a real-world regional cohort. Materials and Methods: All 83 men diagnosed with a testicular or extragonadal GCT at a single center in southeastern Türkiye between 2007 and 2025 were analyzed retrospectively after re-verification of source records. Patients were grouped by clinical stage and by pathology-reported histology. International Germ Cell Cancer Collaborative Group (IGCCCG) risk was recalculated from primary site, metastatic sites, and pre-chemotherapy markers. Overall survival (OS) and progression-free survival (PFS) were estimated using Kaplan–Meier methods and are reported descriptively. Results: Twenty-five patients had N0M0 disease, 27 had stage II, and 31 had stage III disease; nine had an extragonadal primary. Median follow-up was 84.4 months. In N+ or M1 disease (n = 58), 5-year OS was 82.3% (95% confidence interval [CI], 69.6–90.1) and PFS was 63.1% (95% CI, 48.5–74.6); 5-year OS was 95.7% in stage II and 70.5% in stage III. Twenty-three of 47 metastatic nonseminomas (48.9%) were IGCCCG poor risk; 5-year OS was 100%, 83.3%, and 60.2% in the good-, intermediate-, and poor-risk groups. No event occurred among 11 patients with metastatic seminoma. In N0M0 disease, four events occurred among 25 patients, all in seminoma: two relapses in the two patients managed by surveillance, one relapse after adjuvant carboplatin, and one death from pulmonary thromboembolism. Nine patients received high-dose chemotherapy with autologous transplantation; five were alive at last follow-up. Conclusions: This cohort was characterized by a high proportion of poor-risk metastatic nonseminoma, while outcomes within recalculated IGCCCG groups were broadly in line with published series. Histology-specific differences largely reflected stage, risk distribution, and initial management and should be regarded as descriptive.

Authors

Institutions

Publication Details

Journal
Medicina
Published
2026-11-17
DOI
https://doi.org/10.3390/medicina62112249
Primary Topic
Testicular diseases and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Disease Extent, Histology, and Long-Term Outcomes in Male Germ Cell Tumors: A Retrospective Cohort Study

Fatma Keskin Uzundere, Zuhat Urakçı
1 links
Medicina
Testicular diseases and treatments
article

Disease Extent, Histology, and Long-Term Outcomes in Male Germ Cell Tumors: A Retrospective Cohort Study

Fatma Keskin Uzundere, Zuhat Urakçı
article en

Abstract

Background and Objectives: Germ cell tumors (GCTs) are highly curable, but outcomes vary by stage, prognostic risk, and delivery of treatment. We describe presentation, treatment, and long-term outcomes in a real-world regional cohort. Materials and Methods: All 83 men diagnosed with a testicular or extragonadal GCT at a single center in southeastern Türkiye between 2007 and 2025 were analyzed retrospectively after re-verification of source records. Patients were grouped by clinical stage and by pathology-reported histology. International Germ Cell Cancer Collaborative Group (IGCCCG) risk was recalculated from primary site, metastatic sites, and pre-chemotherapy markers. Overall survival (OS) and progression-free survival (PFS) were estimated using Kaplan–Meier methods and are reported descriptively. Results: Twenty-five patients had N0M0 disease, 27 had stage II, and 31 had stage III disease; nine had an extragonadal primary. Median follow-up was 84.4 months. In N+ or M1 disease (n = 58), 5-year OS was 82.3% (95% confidence interval [CI], 69.6–90.1) and PFS was 63.1% (95% CI, 48.5–74.6); 5-year OS was 95.7% in stage II and 70.5% in stage III. Twenty-three of 47 metastatic nonseminomas (48.9%) were IGCCCG poor risk; 5-year OS was 100%, 83.3%, and 60.2% in the good-, intermediate-, and poor-risk groups. No event occurred among 11 patients with metastatic seminoma. In N0M0 disease, four events occurred among 25 patients, all in seminoma: two relapses in the two patients managed by surveillance, one relapse after adjuvant carboplatin, and one death from pulmonary thromboembolism. Nine patients received high-dose chemotherapy with autologous transplantation; five were alive at last follow-up. Conclusions: This cohort was characterized by a high proportion of poor-risk metastatic nonseminoma, while outcomes within recalculated IGCCCG groups were broadly in line with published series. Histology-specific differences largely reflected stage, risk distribution, and initial management and should be regarded as descriptive.

MedicinaVol. 62(11)
Dicle University (TR), Diyarbakır Gazi Yaşargil Eğitim ve Araştırma Hastanesi (TR)
Good health and well-being
Testicular diseases and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon